PLUS THERAPEUTICS is focused on developing innovative, targeted radiotherapeutics for adult and pediatric patients worldwide with rare and difficult-to-treat cancers. These are incurable and often fatal diseases for which there are few good treatment options. PLUS THERAPEUTICS is looking to offer novel treatments with potentially improved safety, efficacy, and convenience to these patients and their healthcare providers.
Our lead product candidate, 186RNL (BMEDA-Chelated Rhenium-186 NanoLiposome) is designed and intended to treat various central nervous system (CNS) tumors.
Central Nervous System (CNS) Tumors
Our pipeline is founded upon promising data generated in a variety of preclinical studies and company-sponsored clinical trials.
186RNL (BMEDA-Chelated Rhenium-186 NanoLiposome)
|Recurrent Glioblastoma||Intratumoral||+ FDA Orphan Drug|
+ FDA Fast Track
|NIH/NCI||ReSPECT-GBM Phase 1 Clinical Trial (Enrolling)|
|Leptomeningeal Metastases||Intrathecal||ReSPECT-LM Phase 1 Clinical Trial (Pre-FDA IND)|
|Pediatric Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)||Intratumoral||ReSPECT-PBC Phase 1 Clinical Trial (Pre-FDA IND)|
|Pediatric Recurrent Ependymoma||Intratumoral||ReSPECT-PBC Phase 1 Clinical Trial (Pre-FDA IND)|
|Pediatric Recurrent High-Grade Glioma (HGG)||Intratumoral||ReSPECT-PBC Phase 1 Clinical Trial (Pre-FDA IND)|
|Peritoneal Carcinomatosis||Intraperitoneal||Late-Stage Preclinical|
|Head & Neck Squamous Cell Carcinoma||Intratumoral||Late-Stage Preclinical|